CompletedInterventionalPhase 2Last updated Apr 26, 2021

A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer

A Phase 2 BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer

Overview

ClinicalTrials.gov ID: NCT02960906
Lead Sponsor: Association Pour La Recherche des Thérapeutiques Innovantes en CancérologieOTHER
Brief Summary: Disease and Stage: naïve metastatic kidney cancer.

A multicenter, randomized, a Phase 2 BIOmarker driven trial with Nivolumab and Ipilimumab or VEGFR tKi in naïve metastatic Kidney cancer
Study Type: Interventional

Status

Overall Status: Completed
Start Date: May 31, 2017Actual
Primary Completion Date: Feb 15, 2021Actual
Completion Date: Feb 15, 2021Actual

Study Record Dates

First Submitted: Aug 18, 2016
First Submitted that Met QC Criteria: Nov 8, 2016
First Posted: Nov 10, 2016Estimated
Last Update Submitted that Met QC Criteria: Apr 22, 2021
Last Update Posted: Apr 26, 2021Actual
Last Verified: Apr 2021

NCT03873402Active, not recruiting

A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer

NCT03297593Completed

Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma

NCT06364631Recruiting

CARE1 Pragmatic Clinical Trial

NCT03274258Terminated

Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma

NCT01472081Completed

Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)

NCT03138512Completed

A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney